{
    "organizations": [],
    "uuid": "d7bea13efebdde0fbd3e8036445f9d4108a7ed9b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-transgene-q1-operating-revenue-sta/brief-transgene-q1-operating-revenue-stable-at-1-8-million-euros-idUSFWN1S31IQ",
    "ord_in_thread": 0,
    "title": "Transgene Q1 Operating Revenue Stable At 1.8 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Transgene SA:\n* TRANSGENE: â‚¬35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018\n* CLINICAL TRIALS NOW ON-GOING WITH 5 IMMUNO-THERAPEUTICS\n* CLINICAL READOUTS EXPECTED FOR EACH OF OUR 5 PRODUCTS IN 2018\n* Q1 OPERATING REVENUE EUR 1.8 MILLION VERSUS EUR 1.9 MILLION YEAR AGO\n* TRANSGENE EXPECTS ITS CASH BURN FOR 2018 TO BE COMPARABLE TO 2017\n* TRANSGENE CONFIRMS THAT IT EXPECTS READOUTS IN 2018 FOR EACH OF ITS 5 PRODUCTS IN CLINICAL DEVELOPMENT Source text for Eikon: (Gdynia Newsroom)\n ",
    "published": "2018-04-27T00:40:00.000+03:00",
    "crawled": "2018-04-27T16:36:55.019+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "transgene",
        "sa",
        "transgene",
        "million",
        "cash",
        "cash",
        "equivalent",
        "march",
        "clinical",
        "trial",
        "clinical",
        "readout",
        "expected",
        "product",
        "q1",
        "operating",
        "revenue",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "transgene",
        "expects",
        "cash",
        "burn",
        "comparable",
        "transgene",
        "confirms",
        "expects",
        "readout",
        "product",
        "clinical",
        "development",
        "source",
        "text",
        "eikon",
        "gdynia",
        "newsroom"
    ]
}